Dr Emma Allot

Dr Emma Allott is a molecular cancer epidemiologist whose research integrates epidemiologic methods and design with molecular tumour profiling to identify mechanisms linking dietary and lifestyle factors with cancer risk and progression. She directs -omics and immunohistochemistry analyses of archival tissue specimens to generate molecular epidemiology resources, and leads a research program focused on the role of statin use, high serum cholesterol and dysregulated tumour lipid metabolism in prostate cancer progression. Dr Allott completed her Ph.D. in molecular cancer biology at Trinity College Dublin, and went on to do a Cancer Prevention, Detection and Control Fellowship at Duke University, using mouse models to study the role of serum cholesterol in prostate tumour growth alongside epidemiologic analyses of associations between serum lipids, statin use and prostate cancer in human studies. She continued her epidemiology training as a postdoc in the Department of Epidemiology at the University of North Carolina Chapel Hill where she had a leadership role in tumour subtyping efforts in the Carolina Breast Cancer Study and AMBER breast cancer consortium.

In 2015, Dr Allott joined the University of North Carolina faculty as an Assistant Professor in the Department of Nutrition, supported by the American Institute for Cancer Research Marilyn Gentry fellowship. In 2017, she was awarded the first Irish Cancer Society John Fitzpatrick Research Fellowship, a partnership between Trinity College Dublin, the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute, to study the role of lipids in treatment response and prostate cancer outcomes. In August 2018, she was appointed Lecturer in Molecular Epidemiology and Nutrition at Queen’s University Belfast. Dr. Allott maintains active roles as Adjunct Assistant Professor at Trinity College Dublin and as a Visiting Scientist at the Harvard T.H. Chan School of Public Health. She serves as Associate Editor for the journal Cancer Causes and Control, and is a member of the multinational Transdisciplinary Prostate Cancer Partnership (ToPCaP), the National Prostate Cancer Research Consortium, the American and Irish Associations for Cancer Research, as well as the Irish Cancer Epidemiology Network